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Abstract
One limitation associated with the delivery of bioactive agents concerns the short half-life of these molecules when administered intra-
venously, which results in their loss from the desired site. Incorporation of bioactive agents into depot vehicles provides a means to
increase their persistence at the disease site. Major issues are involved in the development of a proper carrier system able to deliver
the correct drug, at the desired dose, place and time. In this work, starch-poly-e-caprolactone (SPCL) microparticles were developed
for use in drug delivery and tissue engineering (TE) applications. SPCL microparticles were prepared by using an emulsion solvent
extraction/evaporation technique, which was demonstrated to be a successful procedure to obtain particles with a spherical shape (par-
ticle size between 5 and 900 lm) and exhibiting different surface morphologies. Their chemical structure was confirmed by Fourier trans-
form infrared spectroscopy. To evaluate the potential of the developed microparticles as a drug delivery system, dexamethasone (DEX)
was used as model drug. DEX, a well-known component of osteogenic differentiation media, was entrapped into SPCL microparticles at
different percentages up to 93%. The encapsulation efficiency was found to be dependent on the polymer concentration and drug-to-poly-
mer ratio. The initial DEX release seems to be governed mainly by diffusion, and it is expected that the remaining DEX will be released
when the polymeric matrix starts to degrade. In this work it was demonstrated that SPCL microparticles containing DEX can be suc-
cessfully prepared and that these microparticular systems seem to be quite promising for controlled release applications, namely as car-
riers of important differentiation agents in TE.
! 2008 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
Materials of natural origin have been studied and pro-
posed for a wide range of biomedical applications [1–4].
Materials such as collagen, alginate, hyaluronic acid, silk
fibroin, chitosan and starch are among the most studied
polymers with numerous advantages depending on the spe-
cific applications [5–13]. One of the most relevant benefits
of using materials of natural origin is their biodegradability
inside the human body. Biodegradable systems have the
ability to function satisfactorily for a certain time and sub-
sequently to degrade into products easily cleared from the
body, with no need for surgery for their removal. This is a
particularly desirable property for the design of carriers for
the controlled delivery of therapeutic drugs, since it will
permit the entrapped drug to be released slowly, allowing
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repeating dosages and ensuring the successful effect of the
treatments [14] as the polymer carrier degrades.
Starch-based polymers have been studied and proposed
in the last decade by Reis and coworkers [13,15–21] for sev-
eral biomedical applications, such as drug delivery carrier
systems, hydrogels and partially degradable bone cements,
materials for bone replacement/fixation or fillers for bone
defects, and porous structures to be used as scaffolds in tis-
sue engineering of bone and cartilage. These materials were
found to be biocompatible [16,22–23], noncytotoxic, biode-
gradable [24–27] and have shown a great processing
versatility [13]. These blended materials have potential
application as carriers for the controlled release of different
bioactive agents in the form of microparticular systems.
Indeed, biodegradable starch-based microparticles have
been widely investigated and proposed as drug delivery sys-
tems [28–30]. For instance, starch microparticles using sol-
uble potato starch have been developed and proposed for
the release of a nonsteroidal anti-inflammatory drug [21].
Moreover, a blend of starch and polylactic acid have been
used for the encapsulation of steroids, growth factors and
bioactive glass in a microparticle system [31–33]. These
studies showed that the starch–polylactic acid microparti-
cles are suitable carriers for the controlled release of bioac-
tive agents for bone tissue engineering applications. In
addition, derivatives of starch, such as starch acetate or
poly(acryl starch), have been described for the incorpora-
tion and release of peptides and proteins [34–36]. However,
to our knowledge there has so far been no report in the lit-
erature on the development of microparticle systems based
on starch–polycaprolactone blended materials. The combi-
nation of a hydrophilic natural material (starch) with a
hydrophobic synthetic polymer (polycaprolactone), both
biodegradable and biocompatible, in a single blended
material constitutes the major advantage of these
microparticles.
Numerous controlled release systems have been devel-
oped, ranging from implants [37,38] to novel osmotically
driven pills [38]. The use of noninvasive delivery methods,
such as injectable systems in the form of nano and micro-
particles, will bring substantial benefits when compared
with some surgical techniques. It has already been reported
that injectable systems made of nano and microparticles
could be applied as carriers of different drugs and bioactive
agents within the field of tissue engineering (e.g. differenti-
ation agents and growth factors [39,40]). Dexamethasone
(DEX) has been widely used in clinical applications to treat
immuno-disorders [41,42], but a more specific and common
use has been the control of the inflammatory response and
tissue repair during organ transplantation [43]. In the last
years, the use of this corticosteroid as an osteogenic agent
has increased considerably in in vitro cell culture to induce
the differentiation of stem cells into an osteoblastic lineage
[41,44–46].
This study aims to establish experimental conditions for
the production of a biodegradable and biocompatible
microparticular system with different characteristics (e.g.
size, size distribution, surface morphology) that can be
used as a potential carrier for the delivery of important bio-
active agents. For that, we have used a polymeric blend of
starch with polycaprolactone. The microparticular system
was characterized in terms of particle size, size distribution,
surface morphology and chemical structure. The carrier
potential was evaluated by encapsulating DEX into the
microparticles and its release behavior studied in vitro.
2. Materials and methods
2.1. Materials
A polymeric blend of corn starch with poly-e-caprolac-
tone (SPCL, 30–70 wt.%) was used in this study. More
details about the thermal properties of this polymeric blend
can be found elsewhere [47]. Methylene chloride and polyvi-
nyl alcohol (PVA) were obtained from Sigma, and used as
received. Unless otherwise indicated, the molecular weight
(MW) of the PVA used was in the range 30,000–70,000 g
mol!1 DEX (97%, cell culture tested, Sigma) was used as a
bioactive molecule for the encapsulation studies. Solvents
for high-performance liquid chromatography (HPLC) (ace-
tonitrile and water) were HPLC grade (LABSCAN). Triam-
cinolone was used as internal standard for DEX
quantification. Potassium bromide (KBr) for IR spectros-
copy (P99.5%) was obtained from Sigma. Other chemicals
were of reagent grade, all from Sigma, and used as received.
2.2. Preparation of SPCL microparticles
SPCL microparticles were prepared by using an emul-
sion solvent extraction/evaporation technique [48]. Briefly,
SPCL was dissolved in 5 ml of methylene chloride under
vigorous stirring. This solution was dropped into a
200 ml PVA solution, and emulsified for 4 h at different
stirring rates. Different experimental conditions were eval-
uated, and the details of each condition are summarized in
Table 1. The microparticles where then collected by filtra-
tion, washed with distilled water and vacuum dried in a
desiccator. For the selected condition to be loaded with
DEX, SPCL was mixed with the steroid at different per-
centages (5, 10 and 15% (w/w), relatively to polymer
weight) and dissolved in methylene chloride. The same pro-
cedure was performed as described for unloaded micropar-
ticles. The reaction medium was stored at 4 "C for later
quantification of unloaded DEX. All experiments were car-
ried out in triplicate.
2.3. Physicochemical characterization of SPCL
microparticles
2.3.1. Morphological analysis: scanning electron microscopy
(SEM) and micro-computed tomography (l-CT)
To analyze the morphology and surface of the micropar-
ticles obtained under the different experimental conditions,
the samples were mounted onto aluminium stubs with a
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carbon tape and gold sputter-coated (Fisons Instruments,
Sputter Coater SC502, UK). All images were collected with
a Leica Cambridge S-360 model (Cambridge, UK) scan-
ning electron microscope.
Microparticle samples with porous surfaces (experi-
mental condition III, see Table 1 for details) were
scanned by micro-computed tomography (l-CT) using
a l-CT 20 equipment (SCANCO Medicals, Switzerland).
The energy of the scanner used was 100 kv/98 lA inten-
sity. A threshold range of values of 141–255 was used to
estimate the porosity of the samples. Approximately 40
slices of the sample were obtained. Mimics (Materialise,
Belgium), CT Analyser and CT Vol Realistic 3D Visual-
ization (SkyScan, Belgium) software were used for image
processing and to create and visualize the three-dimen-
sional representation.
2.3.2. Size distribution
To determine the size distribution of the microparticles
obtained under the different experimental conditions, the
microparticles were separated through a series of standard
sieves (20, 60, 100, 125, 150, 250, 450, 500, 650, 900 and
1000 lm; Linker Industrie-Technik, Germany). The micro-
particle fraction that passed through a sieve and was
retained on the sieve with a certain pore size was collected
and weighed, and finally correlated with the total mass of
the microparticle sample analyzed.
2.3.3. Fourier transform infrared (FTIR) spectroscopy
The chemical structure of the microparticles (unloaded,
loaded with DEX and after release) was analyzed by FTIR
(IRPrestige-21 FRIT-8400S, Shimadzu, Japan) in trans-
mission mode. For that, microparticles (1 mg) were mixed
with KBr (40 mg) and then formed into a disc in a manual
press (161–1100 hand press, Pike Technologies, Madison,
WI). Transmission spectra were recorded using at least 32
scans with 4 cm!1 resolution, in the spectral range 4000–
600 cm!1.
2.3.4. X-ray diffraction (XRD)
In order to confirm the encapsulation and release of
DEX into and from the SPCL microparticles, and to access
the physical state of the entrapped drug, X-ray diffraction
patterns of DEX and SPCL microparticles (unloaded,
loaded with DEX and after the release studies) were
obtained in a X-ray diffractometer (X’Pert MPD, Philips,
The Netherlands). The data collection was performed with
a Cu anode and monochromator used at a voltage of
40 kV. The samples were analyzed over the angle range
(2h) 2"–60".
2.4. Determination of DEX encapsulation efficiency and
release profile from SPCL microparticles
2.4.1. Encapsulation efficiency
The encapsulation efficiency of DEX into the SPCL
microparticles was calculated using the following equation:
% Encapsulation eff " ¼ ðCi ! CrÞ=Ci½ ' ( 100; ð1Þ
where Ci is the initial concentration of DEX added, and Cr
is the concentration of unloaded DEX (remaining in the
reaction medium: PVA solution where loaded microparti-
cles were produced). DEX concentration was determined
by HPLC (see Section 2.5). Determinations were made in
triplicate and the average is reported.
2.4.2. In vitro release of DEX from SPLC microparticles
Pre-weighed SPCL–DEX-loaded microparticles were
suspended in 40 ml of PBS (pH 7.4, 0.01 M) at a concentra-
tion of 2.5 mg ml!1. The microparticles were maintained at
37 "C under constant agitation (50 rpm) for 30 days in a
shaking bath. At predetermined time points, first each
30 min, then each 1 and 2 h, and 4, 5, 7, 10, 14, 30 days,
Table 1
Effect of the experimental conditions employed during microparticle production on the size and morphology of the resulting microparticles.
Condition SPCLa
(%)
Emulsification medium PVAb (%) [MW
(g mol!1)]
Stirring rate
(rpm)
Reaction time
(h)
Particle size
(lm)
Shape/surfacec
(SEM)
I 5 1 600 4 102.3 ± 4.1 s/s
II 5 0.5 600 4 200.4 ± 3.7 s/s
III 10 0.5 600 4 575.1 ± 4.6 r/p
IV 10 1 [30,000–70,000] 600 4 499.6 ± 4.8 r/p(HP)
V 10 1 [70,000–100,000] 600 4 702.1 ± 19.0 r/p(HPD)
VI 10 1 800 4 283.0 ± 21.0 r/p(HPD)
VII 10 1 400 4 913.7 ± 9.8 r/p(HPD)
VIII 10 2 600 4 376.0 ± 3.2 r/p
IX 10 5 600 4 324.1 ± 15.3 r/p(HPD)
X 15 1 600 4 770.0 ± 8.7 r/p
XI 20 1 600 4 810.0 ± 16.2 r/p(HPD)
XII 10 1 20,000 4 5.73 ± 8.19 s/s
a SPCL, polymeric blend of corn starch with poly-e-caprolactone.
b PVA, polyvinyl alcohol.
c s/s, spherical/smooth; r/p, round/porous; HPD, high polydispersity; HP, highly porous.
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1 ml aliquots of the supernatant were taken and replaced
with the same volume of fresh PBS solution. DEX concen-
tration was quantified by HPLC. All the release experi-
ments were carried out in triplicate and the average is
reported.
2.5. Quantification of DEX by HPLC
Before HPLC analysis, samples from the reaction med-
ium were extracted three times with a mixture of hexane
and ethyl acetate in the same proportions. The final extract
was collected and the solvent allowed to evaporate under
nitrogen flow. The dry extract was reconstituted in a mix-
ture of acetonitrile/water (50:50 v/v, mobile phase) before
analysis. The aliquots from the release medium (PBS solu-
tion containing released DEX) were analyzed directly as
taken.
DEX was quantified by reverse-phase (RP) HPLC.
HPLC was performed on a Jasco PU-2080 Plus system
using a RP-18 column (LiChrospher, 5 lm, Merck, Ger-
many) with acetonitrile/water (50:50 v/v) as mobile phase
at a flow rate of 0.5 ml min!1. Absorbance was moni-
tored at 254 nm (UV detector Jasco 870-UV). The col-
umn was eluted in isocratic conditions over 20 min.
Data acquisition and peak areas were determined with
a Shimadzu C-R6A Chromatopac software. The concen-
tration of DEX was calculated by using a calibration
curve (y = 8697.18 + (1.65 ( 107)x, R2 = 0.9995). Triam-
cinolone was used as internal standard.
3. Results and discussion
3.1. Preparation of SPCL microparticles: evaluation of the
effect of different experimental conditions on particle size and
morphology
In order to optimize the proposed methodology for the
production of SPCL microparticles with different morpho-
logical characteristics and sizes, several experimental con-
ditions were tested (summarized in Table 1).
Four different polymeric (SPCL) concentrations were
studied to investigate the effect of this parameter on the size
and morphology of the microparticles. Fig. 1 shows the
morphological characteristics of the SPCL microparticles
obtained with different polymeric concentrations.
The viscosity of the SPCL solution is directly related to
the polymeric concentration [49]. Consequently, at higher
concentrations of SPCL, there is a rather significant
increase in the viscosity of the solution and, as result, the
size of the drops in the emulsification medium is higher,
which leads to an increase the microparticle size (experi-
mental conditions I, IV, X, XI: see Table 1). It was found
that at polymer concentrations higher than 10% the poly-
dispersity increases due to the higher particle size obtained
under these conditions. It was also observed that at higher
polymeric concentrations, the microparticles exhibit a por-
ous surface, as shown in Fig. 2b and c, when compared
with the smooth morphology of the microparticles
obtained at lower polymer concentrations (Fig. 2a). A rep-
resentative sample (experimental condition IV, Table 1)
Fig. 1. SEM micrographs of SPCL microparticles obtained under different experimental conditions: (a and b) Condition I–SPCL 5%; (c and d) condition
IV–SPCL 10% (see Table 1 for details).
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from porous microparticles was analyzed by micro-CT
scan (Fig. 3). As result, 44% porosity was obtained, which
indicated that 10% of polymer concentration is adequate
for the production of microparticles with a porous
structure.
By means of selecting the polymer concentration in the
range of 5–10%, it is possible to obtain microparticles with
a desired size range (100–600 lm), a narrow size distribu-
tion as illustrated in Fig. 4, and different surface
morphologies.
The effect of the reaction medium composition was also
studied, by the varying the concentration of PVA in the
emulsification medium from 0.5 to 5%. The use of PVA
as an emulsion stabilizer results in a quite successful prep-
aration of SPCL microparticles. By analyzing the results
presented in Table 1, it can be observed that the size of
the microparticles slightly decreases as the PVA concentra-
tion increases (experimental conditions III, IV, VIII, IX:
see Table 1), but this effect was not as significant as the
one observed for the polymer concentration. The spherical
shape of the microparticles is lost as the concentration of
PVA becomes higher than 2%, and the surface of the
microparticles becomes more porous. Analyzing the effect
of PVA molecular weight (MW), it was found a noticeable
increase in the size of the microparticles (experimental con-
ditions IV, V: see Table 1), when the PVA MW range
increased from 30,000–70,000 to 70,000–100,000 g mol!1.
Therefore, a concentration of 0.5 and 1% PVA with a
MW range 30,000–70,000 g mol!1 was selected as opti-
mum, avoiding loss of spherical shapes, deformation of
particles and uncontrolled particle size.
One of the most important factors affecting the micro-
particle size is the stirring speed during their preparation
[50]. It has been already shown in the literature [51] that
by varying the stirring speed from hundreds to thousands
of rpm, micro to nanoparticles can be produced. In our
experiments, we observed that by increasing the stirring
rate, the size of the microparticles drastically decreased
(experimental conditions VII (400 rpm), IV (600 rpm), VI
(800 rpm) and XII (20,000 rpm) in Table 1). In fact, an
increase in the stirring speeds provides higher energy to dis-
perse two immiscible phases (oil in water phase) and form
the emulsion, producing smaller drops of oil phase in the
water (because it is breaking the oil phase into smaller
drops) and as a result smaller particles are obtained.
Fig. 5 shows the morphological characteristics and the size
of the SPCL microparticles obtained with higher stirring
speeds.
3.2. Physicochemical characterization of unloaded SPCL
microparticles
Iodine–potassium solution (Lugol) is a well-known and
useful solution for chemically identifying the presence of
starch molecules [31]. The amylose present in the starch
molecule has a helical secondary structure [52], where sub-
stances such as iodine can lodge, forming a complex as an
inclusion compound. This starch–iodine forms a coloured
complex (dark blue), and this property can be used to iden-
tify the presence and distribution of starch in complex
polymeric blends. Staining with Lugol solution was per-
formed for all experimental conditions. These experiments
revealed the presence of starch in the microparticles, since a
dark blue staining was observed in all conditions. A more
intense staining was observed in the microparticles with a
porous surface. This may due to the diffusion of iodine to
the interior of the microparticles in this case, while in the
microparticles with smooth surface the iodine is mainly
reacting with the starch molecules present at the surface
of the microparticles.
The infrared spectrum of SPCL microparticles exhibits
the same characteristic peaks of the raw material before
processing (the infrared spectrum of SPCL raw material
Fig. 2. SEM micrographs of the surface of SPCL microparticles showing
different morphologies when using different polymer concentrations: (a)
Condition I–SPCL 5%; (b) condition IV–SPCL 10%; (c) condition XI–
SPCL 20% (see Table 1 for details).
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Fig. 3. Micro-CT three-dimensional reconstruction of the SPCL microparticle illustrating the porosity of the obtained particulate structure (experimental
condition IV: see Table 1).
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Fig. 5. SEM micrographs of SPCL microparticles obtained at higher stirring speed, at (a) lower and (b) higher magnification. Condition XII–20,000 rpm,
resulting in a stronger decrease in the size of the resulting microparticles.
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has been described in previous publications [25,53–55]).
The bands from PCL and starch were easily identified.
The strongest bands and their assignments are summarized
in Table 2. This demonstrates that both components of the
blend remained present in the chemical structure of the
obtained microparticles.
3.3. Determination of DEX encapsulation efficiency and
in vitro release profile
For the loading of DEX and in vitro release experi-
ments, conditions I–IV (Table 1) were selected for the prep-
aration of SPCL microparticles. Using these conditions,
DEX-loaded microparticles were successfully produced.
The obtained microparticles exhibited a morphology very
similar to unloaded microparticles (see Figs. 1d and 6 for
morphological comparison). A more compact surface was
found and the particle size slightly increased as result of
DEX entrapment. The quantification of the DEX, before
and after loading, was performed by HPLC.
3.3.1. Encapsulation efficiency
For the determination of the encapsulation efficiency,
the amount of DEX remaining in the reaction medium
(unloaded DEX) was quantified. Table 3 shows the encap-
sulation efficiency values as a function of the initial amount
of DEX added to the polymer solution. Higher values were
obtained when 15% of DEX was added. There is a notable
increase in the encapsulation efficiency when there is an
increment from 5 to 10% in the initial DEX amount. How-
ever, increasing the initial amount of DEX higher than 10%
yielded no significant increase in encapsulation efficiency.
Taking these results into account, 15% was used as the ini-
tial amount of DEX (1:5 drug/polymer ratio) for the
release studies.
3.3.2. In vitro release of DEX from SPLC microparticles
Drug release from a polymeric matrix is controlled by a
variety of factors, such as the solubility of the drug within
the surrounding fluid, the size of the drug molecule and its
mobility within the swollen polymeric network, and the dis-
solution rate of the polymer and polymer–drug interac-
tions. Moreover, several authors have reported that the
release kinetic is dependent on different characteristics of
the microparticles (e.g. type of polymer, particle size and
size distribution, surface morphology) [56–61], and these
features can be controlled by the fabrication conditions.
A number of studies in the literature have investigated
the effect of fabrication conditions (e.g. interconnected
pores and channels, emulsification medium concentration
and polymer concentration) on the morphology of
obtained microparticles, drug distribution and release
kinetics [56–58,60,61]. Thus, understanding the influence
of microparticle characteristics on the release behavior is
important for yielding useful products that can meet differ-
ent clinical applications.
The release profiles of DEX from SPCL microparticles
during 30 days in PBS are illustrated in Fig. 7. The release
in the first day is shown in more detail in the insert. The ini-
tial burst release is attributable to the release of the drug
that is present at the outermost layer of the microparticles
and is released quickly [4,27,62–63]. The burst release is
then followed by a sustained release stage, which is most
likely due to the hydrophobic character of poly(caprolac-
tone) (PCL) polymer present in the microparticles and con-
sequently its corresponding low permeability to water. The
hydrophobicity of PCL (70% in the blend) can cause a
delay in water penetration and, consequently, the diffusion
of the drug through the polymeric matrix into the aqueous
release medium was retarded. On the other hand, it is nec-
essary to take in consideration that the biodegradation of
SPCL in PBS medium is slow [25] when compared with
Table 2
Characteristic IR bands of the microparticle components (starch and
polycaprolactone) [12,27].
cm!1 Vibration Abbreviation
2944/2864 (from PCL) Asymmetric/
symmetric CH2 stretching
tas(CH2), ts(CH2)
1724 C@O stretching t(C@O)
1244 Asymmetric COC stretching tas(COC)
1195 OCAC stretching/symmetric
COC stretching
t(OCAO), ts(COC)
3362 (from starch) OH stretching t(OH)
1021/1048 CAOAC glycosidic bond t(COC)
Table 3
Effect of the initial amount of DEX on its encapsulation efficiency in the
SPCL microparticles.
Condition % SPCL Particle size
(lm)
Drug/polymer
ratio (w/w)
Loading
efficiency (%)
IV-DEX 10 525.3 ± 7.9 1:20 74.99
1:10 90.72
1:5 93.65
Fig. 6. SEM micrographs of SPCL–DEX-loaded microparticles (experi-
mental condition IV: see Table 3).
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other biodegradable polymers. Therefore, at the initial
stages, the release of DEX from the SPCL microparticles
is mainly controlled by diffusion mechanisms, and it is
expected that the remaining drug in the polymeric matrix
will be released as the degradation process becomes more
significant.
When using higher polymer concentrations in the prep-
aration of the microparticles (Fig. 7a and b) the drug
release profile shows a more sustained pattern. This may
be due to the fact that as the SPCL concentration increases,
the particle size also increases, leading to a decrease in the
total surface area of the microparticle system, reducing the
area that is in direct contact with the water.
Further evidence of the loading and release of DEX
from the SPCL microparticles was shown by FTIR analysis
(Fig. 8). The FTIR spectrum of DEX-loaded SPCL micro-
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particles (Fig. 8b) shows the characteristic bands of DEX,
indicating the successful loading of the drug into the micro-
particles. After the release studies, it can be observed that
there is a reduction in the intensity of the characteristic
bands of DEX in the IR spectrum (Fig. 8c), due to the par-
tial release of the drug from the microparticles. This result
further indicates that the DEX present at the outermost
layer of the microparticles is released quickly. The release
profile obtained in this study, with an initial burst stage fol-
lowed by a sustained release (typical of first-order release
kinetic systems), is in accordance with the release behavior
obtained with other delivery systems with similar composi-
tion [64].
The structure of the entrapped drug is also an important
aspect to take into consideration in drug delivery systems,
since it is known that transitions from amorphous to crys-
talline structures may occur. These transitions may affect
the rate of drug release. For this purpose, XRD studies
can show the physical nature of the encapsulated material.
In Fig. 9 XRD diffractograms of DEX, unloaded SPCL
microparticles and SPCL microparticles loaded with
DEX after 30 days of in vitro release are presented. The
XRD pattern of DEX shows several crystalline peaks, as
marked in Fig. 9d. For the DEX-loaded SPCL microparti-
cles it is possible to see the appearance of the characteristic
peaks from the drug at low 2h, between 10" and 20", indi-
cating the crystalline state of the DEX entrapped in the
SPCL matrix. The maintenance of the crystalline structure
may be due to the space available in the polymeric matrix
(e.g. pore formation). Another confirmation of the in vitro
DEX release can be observed in Fig. 9c, where the charac-
teristics peaks of DEX are not observed after 30 days in
PBS.
Several research groups are currently developing con-
trolled release systems in the context of bone tissue engi-
neering with the main goal of inducing in vitro the
osteogenic differentiation of stem cells. A common problem
associated with some of these systems is still in the lack of
control over the drug release. Therefore, in this study we
propose a very attractive drug delivery system, consisting
of SPCL microparticles that can present diverse character-
istics depending on the experimental conditions used dur-
ing processing. The processing method can be adjusted to
obtain particles with different sizes in the micron range,
as well as with distinct surface morphologies from smooth
to porous. Moreover, the developed SPCL microparticles
were found to be biodegradable, noncytotoxic and biocom-
patible, as reported in a previous study [27]. The in vitro
release studies of DEX, a widely used osteogenic agent,
showed a sustained release pattern for a period of 30 days,
indicating that the developed system might be very useful
for the induction of osteoblastic differentiation of stem
cells.
Further studies will be carried out in order to study the
release behavior of DEX or other bioactive agents in the
presence of enzymes in order to investigate the effect of
matrix degradation on the release kinetics.
4. Conclusions
In this work the production of polymeric microparticles
made from a blend of starch with polycaprolactone (SPCL)
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Fig. 9. XRD diffractograms of SPCL microparticles: (a) unloaded; (b) loaded with DEX; (c) DEX-loaded microparticles after 30 days of release; (d) DEX.
The characteristics peaks of DEX are marked (j).
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by means of an emulsion solvent evaporation technique
was evaluated. Microparticles with different morphologies
(smooth and porous) and sizes between 5 and 900 lm could
be obtained by using this methodology. Encapsulation of
DEX into SPCL microparticles was performed with high
encapsulation efficiencies, up to 93%. The in vitro release
studies showed a sustained release pattern for a period of
30 days, indicating the carrier potential of SPCL micropar-
ticles for the delivery of important bioactive agents. The
developed systems might be very useful in the in vitro cul-
turing of stem cells aimed at being committed into the
osteoblastic lineage.
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